EU Approves Daratumumab Triplets for Myeloma

May 1, 2017 – The European Commission (EC) has approved daratumumab for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma following at least 1 prior therapy, based primarily on findings from the phase III POLLUX and CASTOR studies. In the POLLUX trial, adding the CD38-targeted antibody daratumumab to lenalidomide and dexamethasone reduced the risk of … (leggi tutto)